Novel protein interactors of urokinase-type plasminogen activator receptor

Biochemical and Biophysical Research Communications

Volumn 399, Issue 4, 2010, Pages 738-743

  Mekkawy, Ahmed H ^a   De Bock, Charles E ^a   Lin, Zhen ^a   Morris, David L ^a   Wang, Yao ^a   Pourgholami, Mohammad H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Breast cancer; HAX1; HSpry1; Protein protein interaction; UPAR; Yeast two hybrid

Indexed keywords

BINDING PROTEIN; COMPLEMENTARY DNA; HS1 BINDING PROTEIN; SPROUTY PROTEIN; SPROUTY PROTEIN 1; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; HAX1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SPRY1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER SCREENING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA LIBRARY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; TWO HYBRID SYSTEM; YEAST; BREAST TUMOR; CELL LINE; FEMALE; GENE LIBRARY; GENETICS; METABOLISM; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; FEMALE; GENE LIBRARY; HUMANS; IMMUNOPRECIPITATION; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PHOSPHOPROTEINS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 77956263776     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.010     Document Type: Article

References (42)

1. Mekkawy A.H., Morris D.L., Pourgholami M.H. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 2009, 5:1487-1499.
2. Preissner K.T., Kanse S.M., May A.E. Urokinase receptor: a molecular organizer in cellular communication. Curr. Opin. Cell Biol. 2000, 12:621-628.
3. Kanse S.M., Kost C., Wilhelm O.G., Andreasen P.A., Preissner K.T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 1996, 224:344-353.
4. Colman R.W. Role of the light chain of high molecular weight kininogen in adhesion, cell-associated proteolysis and angiogenesis. Biol. Chem. 2001, 382:65-70.
5. Ploug M., Ronne E., Behrendt N., Jensen A.L., Blasi F., Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J. Biol. Chem. 1991, 266:1926-1933.
6. Myöhänen H.T., Stephens R.W., Hedman K., Tapiovaara H., Rønne E., Høyer-Hansen G., Danø K., Vaheri A. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J. Histochem. Cytochem. 1993, 41:1291-1301.
7. Llinas P., Le Du M.H., Gårdsvoll H., Danø K., Ploug M., Gilquin B., Stura E.A., Ménez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005, 24:1655-1663.
8. Carriero M.V., Del Vecchio S., Capozzoli M., Franco P., Fontana L., Zannetti A., Botti G., D'Aiuto G., Salvatore M., Stoppelli M.P. Urokinase receptor interacts with αvβ5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 1999, 59:5307-5314.
9. 2 integrin-dependent leukocyte adhesion involving the urokinase receptor. Blood 2000, 96:506-513.
10. Dalvi N., Thomas G.J., Marshall J.F., Morgan M., Bass R., Ellis V., Speight P.M., Whawell S.A. Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit. Biochem. Biophys. Res. Commun. 2004, 317:92-99.
11. Xue W., Mizukami I., Todd R.F., Petty H.R. Urokinase-type plasminogen activator receptors associate with beta 1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997, 57:1682-1689.
12. Resnati M., Pallavicini I., Wang J.M., Oppenheim J., Serhan C.N., Romano M., Blasi F. Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR). PNAS 2002, 99:1359-1364.
13. Liu D., Aguirre Ghiso J., Estrada Y., Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell. 2002, 1:445-457.
14. Nykjaer A., Conese M., Christensen E.I., Olson D., Cremona O., Gliemann J., Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 1997, 16:2610-2620.
15. Koshelnick Y., Ehart M., Hufnagl P., Heinrich P.C., Binder B.R. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 1997, 272:28563-28567.
16. Tkachuk N., Kiyan J., Tkachuk S., Kiyan R., Shushakova N., Haller H., Dumler I. Urokinase induces survival or pro-apoptotic signals in human mesangial cells depending on the apoptotic stimulus. Biochem. J. 2008, 415:265-273.
17. De Bock C.E., Lin Z., Mekkawy A.H., Byrne J.A., Wang Y. Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. Int. J. Oncol. 2010, 36:1155-1163.
18. Andreasen P.A., Egelund R., Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci. 2000, 57:25-40.
19. Ploug M., Ostergaard S., Hansen L.B., Holm A., Danø K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 1998, 37:3612-3622.
20. Ploug M., Rahbek-Nielsen H., Ellis V., Roepstorff P., Danø K. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochemistry 1995, 34:12524-12534.
21. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb. Haemost. 1999, 82:298-304.
22. Wahlberg K., Høyer-Hansen G., Casslén B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res. 1998, 58:3294-3298.
23. Byrne J.A., Nourse C.R., Basset P., Gunning P. Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system. Oncogene 1998, 16:873-881.
24. Semple J.I., Prime G., Wallis L.J., Sanderson C.M., Markie D. Two-hybrid reporter vectors for gap repair cloning. Biotechniques 2005, 38:927-934.
25. de Bock C.E., Lin Z., Itoh T., Morris D., Murrell G., Wang Y. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. Eur. J. Biochem. 2005, 272:3572-3582.
26. Taniguchi K., Ayada T., Ichiyama K., Kohno R., Yonemitsu Y., Minami Y., Kikuchi A., Maehara Y., Yoshimura A. Sprouty2 and Sprouty4 are essential for embryonic morphogenesis and regulation of FGF signaling. Biochem. Biophys. Res. Commun. 2007, 352:896-902.
27. Kim H.J., Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat. Rev. Mol. Cell. Biol. 2004, 5:441-450.
28. Impagnatiello M.A., Weitzer S., Gannon G., Compagni A., Cotten M., Christofori G. Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J. Cell Biol. 2001, 152:1087-1098.
29. Schwab W., Gavlik J.M., Beichler T., Funk R.H., Albrecht S., Magdolen V., Luther T., Kasper M., Shakibaei M. Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1-integrin. Histochem. Cell Biol. 2001, 115:317-323.
30. Stahl A., Mueller B.M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J. Cell Biol. 1995, 129:335-344.
31. Wei Y., Yang X., Liu Q., Wilkins J.A., Chapman H.A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 1999, 144:1285-1294.
32. Hanafusa H., Torii S., Yasunaga T., Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol. 2002, 4:850-858.
33. Lo T.L., Yusoff P., Fong C.W., Guo K., McCaw B.J., Phillips W.A., Yang H., Wong E.S., Leong H.F., Zeng Q., Putti T.C., Guy G.R. The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res. 2004, 64:6127-6136.
34. Schaaf G., Hamdi M., Zwijnenburg D., Lakeman A., Geerts D., Versteeg R., Kool M. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res. 2010, 70:762-771.
35. Suzuki Y., Demoliere C., Kitamura D., Takeshita H., Deuschle U., Watanabe T. HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases. J. Immunol. 1997, 158:2736-2744.
36. Gallagher A.R., Cedzich A., Gretz N., Somlo S., Witzgall R. The polycystic kidney disease protein PKD2 interacts with Hax-1, a protein associated with the actin cytoskeleton. Proc. Natl. Acad. Sci. USA 2000, 97:4017-4022.
37. Fadeel B., Grzybowska E. HAX-1: a multifunctional protein with emerging roles in human disease. Biochim. Biophys. Acta 2009, 1790:1139-1148.
38. Kumamoto H., Ooya K. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors. J. Oral Pathol. Med. 2007, 36:488-494.
39. Dublin E., Hanby A., Patel N.K., Liebman R., Barnes D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am. J. Pathol. 2000, 157:1219-1227.
40. El-Kott A.F., Khalil A.M., El-Kenawy A.-M. Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma. Int. Urol. Nephrol. 2004, 36:417-423.
41. Li P., Gao Y., Ji Z., Zhang X., Xu Q., Li G., Guo Z., Zheng B., Guo X. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma. J. Pediatr. Surg. 2004, 39:1512-1519.
42. Andreasen P.A., Nielsen L.S., Kristensen P., Grondahl-Hansen J., Skriver L., Dano K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem. 1986, 261:7644-7651.